药学学报
藥學學報
약학학보
ACTA PHARMACEUTICA SINICA
2001年
3期
179-184
,共6页
徐柏玲%郭宗儒%梁晓天%褚凤鸣%王乃功%关慕贞
徐柏玲%郭宗儒%樑曉天%褚鳳鳴%王迺功%關慕貞
서백령%곽종유%량효천%저봉명%왕내공%관모정
抗雌激素受体活性%三苯乙烯
抗雌激素受體活性%三苯乙烯
항자격소수체활성%삼분을희
目的为寻找高效低毒的雌激素受体拮抗剂,设计合成了新结构骨架的三苯乙烯类化合物。方法通过McMurry反应得到三苯乙烯中间体,再经醚化反应得到目的物。通过抗小鼠子宫增重实验测定化合物的拮抗活性,竞争性结合雌激素受体实验测定化合物对受体的亲和力。结果本文共合成了35个新化学实体,并利用X-射线晶体衍射和氢谱确定了化合物的构型。结论所有化合物均能与受体结合(IC50<10-6 mol.L-1),其中化合物35与受体的亲和力最大。某些化合物抑制子宫的增长,表现为拮抗作用;有的则促进子宫的增长,表现为激动作用。其中化合物14和27对子宫的抑制作用强于或相当于他莫昔芬,有待进一步研究。
目的為尋找高效低毒的雌激素受體拮抗劑,設計閤成瞭新結構骨架的三苯乙烯類化閤物。方法通過McMurry反應得到三苯乙烯中間體,再經醚化反應得到目的物。通過抗小鼠子宮增重實驗測定化閤物的拮抗活性,競爭性結閤雌激素受體實驗測定化閤物對受體的親和力。結果本文共閤成瞭35箇新化學實體,併利用X-射線晶體衍射和氫譜確定瞭化閤物的構型。結論所有化閤物均能與受體結閤(IC50<10-6 mol.L-1),其中化閤物35與受體的親和力最大。某些化閤物抑製子宮的增長,錶現為拮抗作用;有的則促進子宮的增長,錶現為激動作用。其中化閤物14和27對子宮的抑製作用彊于或相噹于他莫昔芬,有待進一步研究。
목적위심조고효저독적자격소수체길항제,설계합성료신결구골가적삼분을희류화합물。방법통과McMurry반응득도삼분을희중간체,재경미화반응득도목적물。통과항소서자궁증중실험측정화합물적길항활성,경쟁성결합자격소수체실험측정화합물대수체적친화력。결과본문공합성료35개신화학실체,병이용X-사선정체연사화경보학정료화합물적구형。결론소유화합물균능여수체결합(IC50<10-6 mol.L-1),기중화합물35여수체적친화력최대。모사화합물억제자궁적증장,표현위길항작용;유적칙촉진자궁적증장,표현위격동작용。기중화합물14화27대자궁적억제작용강우혹상당우타막석분,유대진일보연구。
AIM In order to improve the biological activity and reduce the side effects and toxicity, a series of novel estrogen receptor antagonists were designed. METHODS The key triphenylethylene intermediates were obtained by the McMurry reaction. The target compounds were prepared by etherification. The binding affinities of the target compounds for the estrogen receptor in rat uterine cytosol were measured by a competitive binding assay and their estrogen agonistic/antagonistic properties were investigated in the 3-day uterine weight assay in the immature rats. RESULTS Thirty-five new compounds have been synthesized and their geometric configuration were determined by X-ray crystallography and 1HNMR spectral data. CONCLUSION All of the test compounds showed affinity for the estrogen receptor (IC50<10-6 mol.L-1), especially compound 35 with IC50 1.07×10-8 mol.L-1. Some compounds are antagonists, inhibiting uterus growth; others are agonists, promoting uterus growth. Compounds 14 and 27 are superior antagonists to tamoxifen.